bosentan anhydrous has been researched along with Respiratory Distress Syndrome in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fraidenburg, DR; Guo, Q; Huang, JA | 1 |
| Guimarães, CL; Rae, GA; Trentin, PG | 1 |
| Abdel Kafi, S; Bejjani, G; Biarent, D; Hubloue, I; Leeman, M; Mélot, C; Naeije, R | 1 |
| Behrends, M; Beiderlinden, M; Peters, J | 1 |
| Couture, R; Da-Silva, S; Guimarães, CL; Rae, GA | 1 |
| Belvisi, MG; Birrell, MA; Foster, ML; Hele, DJ; Webber, SE | 1 |
6 other study(ies) available for bosentan anhydrous and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Bosentan as rescue treatment in refractory hypoxemia and pulmonary hypertension in a patient with ARDS and H7N9 influenza virus infection.
Topics: Antihypertensive Agents; Antiviral Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Hypoxia; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Positive-Pressure Respiration; Respiratory Distress Syndrome; Sulfonamides; Treatment Outcome | 2014 |
Endothelin ET(B) receptor-mediated mechanisms involved in oleic acid-induced acute lung injury in mice.
Topics: Acute Disease; Analysis of Variance; Animals; Atrasentan; Bosentan; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Evans Blue; Lung; Male; Mice; Mice, Inbred Strains; Neutrophil Infiltration; Oleic Acid; Pyrimidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Respiratory Distress Syndrome; Sulfonamides | 2002 |
Endothelin receptor blockade in canine oleic acid-induced lung injury.
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Infusions, Intravenous; Oleic Acid; Prospective Studies; Pulmonary Circulation; Pulmonary Gas Exchange; Pulmonary Wedge Pressure; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Respiratory Distress Syndrome; Sulfonamides; Vascular Resistance | 2003 |
Combination of sildenafil and bosentan for nitric oxide withdrawal.
Topics: Antihypertensive Agents; Bosentan; Extracorporeal Membrane Oxygenation; Female; Humans; Middle Aged; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Respiratory Distress Syndrome; Sildenafil Citrate; Substance Withdrawal Syndrome; Sulfonamides; Sulfones; Vasodilator Agents; Ventilator Weaning | 2005 |
Mixed endothelin ET(A) and ET(B) antagonist bosentan inhibits oleic acid-induced lung plasma extravasation in mouse.
Topics: Animals; Bosentan; Capillary Permeability; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelins; Evans Blue; Male; Mice; Oleic Acid; Receptor, Endothelin A; Receptor, Endothelin B; Respiratory Distress Syndrome; Sulfonamides | 2000 |
Effect of endothelin antagonists, including the novel ET(A) receptor antagonist LBL 031, on endothelin-1 and lipopolysaccharide-induced microvascular leakage in rat airways.
Topics: Animals; Antihypertensive Agents; Bosentan; Capillary Permeability; Endothelin Receptor Antagonists; Endothelin-1; Humans; Infant, Newborn; Lipopolysaccharides; Male; Oligopeptides; Piperidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Respiratory Distress Syndrome; Sulfonamides | 2000 |